BiotechTube
Artcline

Artcline

Munich, Germany· Est.
artcline.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Artcline GmbH, founded in 2007 and based in Munich, is a clinical-stage biotechnology company pioneering an immune cell-based extracorporeal therapy for bacterial sepsis. Its lead program, the patented ARTICE® Therapy, is undergoing final clinical validation in a controlled randomized multicenter study in Germany (ReActIF-ICE), having already obtained initial regulatory approvals. The company is led by a seasoned management team with deep expertise in immunology, biopharmaceuticals, and medical device development, aiming to address a significant unmet medical need with high associated healthcare costs.

SepsisCritical Care

Technology Platform

Patented ARTICE® Therapy, an immune cell-based extracorporeal system for modulating a patient's immune response to treat bacterial sepsis.

Opportunities

The global sepsis market represents a massive unmet need with high mortality and economic burden, creating a multi-billion dollar opportunity for an effective therapy.
Positive results from the ongoing ReActIF-ICE trial could position Artcline for partnership or acquisition by a larger medtech/pharma company, and establish a new standard of care in intensive care units.

Risk Factors

The company faces high clinical risk as its entire value depends on the success of a single late-stage trial in a complex indication.
As a pre-revenue, private company, it carries significant financing risk to complete this trial.
Future market adoption faces challenges of integrating a new procedure into ICU workflows and demonstrating cost-effectiveness.

Competitive Landscape

The competitive landscape for immunomodulatory sepsis therapies is evolving but not yet crowded with approved products. Artcline competes with other biotechs developing antibody-based or cell-based therapies targeting the host immune response, as well as with companies developing novel extracorporeal blood purification devices. Its specific ex vivo immune cell approach appears to be a differentiated strategy.

More companies in Cell & Gene Therapy →More companies in Germany →